Skip to main content

ACC.20/WCC – Bonaca: VOYAGER PAD Trial Summary

ACC.20/WCC – Bonaca: VOYAGER PAD Trial Summary

March 28, 2020

Marc P. Bonaca, MD, Associate Professor and Director of Vascular Research at the University of Colorado School of Medicine and CPC Clinical Research, Aurora, Colorado, discusses his presentation at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) of the VOYAGER PAD trial.

VOYAGER PAD is an international trial designed to evaluate whether rivaroxaban added to aspirin is better than aspirin alone in reducing these events in symptomatic patients undergoing lower limb revascularization. Researchers said this study answers important questions remaining after the COMPASS trial, which demonstrated that low-dose rivaroxaban plus aspirin versus aspirin alone significantly reduced major adverse heart events in stable people with coronary artery disease and PAD.

This study was simultaneously published online in the New England Journal of Medicine at the time of presentation. The study was funded by Bayer AG and Janssen Research and Development.

Learn more about the VOYAGER PAD subgroup analysis presented by William R. Hiatt.

Back to Top